Wafer-scale Graphene Platform for Sensors
Paragraf
The key point is that Paragraf is not building two separate businesses, it is building one manufacturing stack that can feed multiple sensor markets. The same graphene growth process sits underneath both magnetic and molecular sensors, so each new product can ride on the same wafers, tools, packaging lines, and test flow. That matters because graphene has historically struggled to move from lab samples to repeatable chip production at useful volumes.
-
Paragraf grows monolayer graphene directly on silicon wafers with a metal free CVD process, which removes the transfer step used by many graphene makers. In practice, that means fewer handling steps before the chip is diced, packaged, and tested on normal semiconductor equipment, which is the main reason thousands of devices can come off one run.
-
The two product lines are physically different at the use case level, but similar at the fab level. Hall sensors go into systems like quantum computers and EV battery packs to read magnetic fields, while molecular sensors are transistor chips that labs functionalize and expose to liquid or gas samples. Sharing the same wafer platform lets Paragraf spread R&D and factory cost across both.
-
This shared process is also why the Cardea Bio acquisition fit cleanly. Cardea added biosensing IP and US manufacturing capability, while Paragraf kept the same core graphene electronics platform underneath. More recently, the company reported its first 6 inch graphene wafer, which shows the manufacturing base is being pushed toward larger standard formats that should improve throughput further.
From here, the advantage compounds if Paragraf keeps adding products on top of the same graphene wafer process. The more it can turn one materials platform into many sensor SKUs, the more it starts to look less like a custom science supplier and more like a real semiconductor manufacturer with reusable process technology.